Pend­ing FDA's OK, Te­va and Alvotech can bring their Ste­lara biosim­i­lar to US mar­ket by 2025

Alvotech and part­ner Te­va have now con­quered half the hur­dle in bring­ing a Ste­lara biosim­i­lar to mar­ket.

The two com­pa­nies an­nounced Mon­day that they agreed to a set­tle­ment and li­cense agree­ment with John­son & John­son to bring can­di­date AVT04 to US con­sumers by no lat­er than Feb. 21, 2025.

A Janssen rep­re­sen­ta­tive told End­points News in an email on Mon­day that the terms of the agree­ment are con­fi­den­tial, adding that the com­pa­ny “will con­tin­ue to de­fend the in­tel­lec­tu­al prop­er­ty as­so­ci­at­ed with our med­i­cines to pro­tect our abil­i­ty to in­no­vate and de­vel­op life-chang­ing ther­a­pies for pa­tients.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER